1
|
Ballouze R, Ismail MN, Abu Kassim NS, Salhimi SM, Mohamad I, Abd Mutalib NS, Hassim AA, Fazalul Rahiman SS. Detection of dynorphin 1-17 biotransformation fragments in human nasal polyps by UPLC-QTOF-MS. Anal Bioanal Chem 2024; 416:545-557. [PMID: 38040942 DOI: 10.1007/s00216-023-05061-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Revised: 11/06/2023] [Accepted: 11/13/2023] [Indexed: 12/03/2023]
Abstract
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammation of the sinonasal mucosa. CRSwNP treatments are associated with inconsistent efficacy and recurrence of symptoms. Dynorphin 1-17 (DYN 1-17) and its fragments have been shown to modulate the immune response in various inflammatory conditions. This study aimed to investigate the effect of different pH and degrees of inflammation on DYN 1-17 metabolism in human CRSwNP tissues. DYN 1-17 was incubated with grade 3 and grade 4 inflamed tissues of CRSwNP patients at pH 5.5 and pH 7.4 over a range of incubation periods. The resulting fragments were identified using an ultra-performance liquid chromatography (UPLC) system coupled to quadrupole-time of flight (QTOF) mass spectrometry based on their accurate mass. The rate of DYN 1-17 fragmentation was slower at pH 5.5 in comparison to pH 7.4. The extent and rate of metabolism of DYN 1-17 were much lower in grade 3 inflamed tissue (31-32 fragments) than in grade 4 (34-41 fragments). N-Terminal fragments (DYN 1-15, 1-11, 1-10, and 1-6) were metabolized slower at pH 5.5 as compared to pH 7.4. DYN 1-12, 1-8, 2-10, 4-10, 5-10, and 8-14 were only observed under the inflammatory pH while DYN 5-17 and 6-17 were only identified upon incubation with grade 4 CRSwNP tissues. DYN 1-17 metabolism was significantly affected by the pH level and the severity of the inflammation of CRSwNP tissues, indicating the potential roles of DYN 1-17 and its fragments in modulating the inflammatory response and their avenue as therapeutics in future studies.
Collapse
Affiliation(s)
- Rama Ballouze
- School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 USM, Pulau Pinang, Malaysia
| | - Mohd Nazri Ismail
- Analytical Biochemistry Research Centre, Universiti Sains Malaysia, 11900, Bayan Lepas, Pulau Pinang, Malaysia
| | - Nur Sofiah Abu Kassim
- School of Chemistry and Environment, Faculty of Applied Science, Universiti Teknologi MARA, 72000, Kuala Pilah, Negeri Sembilan, Malaysia
| | | | - Irfan Mohamad
- Department of Otorhinolaryngology-Head & Neck Surgery, School of Medical Sciences, Universiti Sains Malaysia Health Campus, 16150, Kota Bharu, Kelantan, Malaysia
| | - Nor Shahida Abd Mutalib
- Department of Otorhinolaryngology-Head and Neck Surgery, Hospital Sultan Abdul Halim, 08000, Sungai Petani, Kedah, Malaysia
| | - Ahmad Anuar Hassim
- School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 USM, Pulau Pinang, Malaysia
| | | |
Collapse
|
2
|
Galante P, Campos GAA, Moser JCG, Martins DB, Dos Santos Cabrera MP, Rangel M, Coelho LC, Simon KS, Amado VM, de A I Muller J, Koehbach J, Lohman RJ, Cabot PJ, Vetter I, Craik DJ, Toffoli-Kadri MC, Monge-Fuentes V, Goulart JT, Schwartz EF, Silva LP, Bocca AL, Mortari MR. Exploring the therapeutic potential of an antinociceptive and anti-inflammatory peptide from wasp venom. Sci Rep 2023; 13:12491. [PMID: 37528129 PMCID: PMC10393941 DOI: 10.1038/s41598-023-38828-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Accepted: 07/16/2023] [Indexed: 08/03/2023] Open
Abstract
Animal venoms are rich sources of neuroactive compounds, including anti-inflammatory, antiepileptic, and antinociceptive molecules. Our study identified a protonectin peptide from the wasp Parachartergus fraternus' venom using mass spectrometry and cDNA library construction. Using this peptide as a template, we designed a new peptide, protonectin-F, which exhibited higher antinociceptive activity and less motor impairment compared to protonectin. In drug interaction experiments with naloxone and AM251, Protonectin-F's activity was decreased by opioid and cannabinoid antagonism, two critical antinociception pathways. Further experiments revealed that this effect is most likely not induced by direct action on receptors but by activation of the descending pain control pathway. We noted that protonectin-F induced less tolerance in mice after repeated administration than morphine. Protonectin-F was also able to decrease TNF-α production in vitro and modulate the inflammatory response, which can further contribute to its antinociceptive activity. These findings suggest that protonectin-F may be a potential molecule for developing drugs to treat pain disorders with fewer adverse effects. Our results reinforce the biotechnological importance of animal venom for developing new molecules of clinical interest.
Collapse
Affiliation(s)
- Priscilla Galante
- Laboratory of Neuropharmacology, Department of Physiological Sciences, University of Brasília, Brasília, DF, 70910-900, Brazil
| | - Gabriel A A Campos
- Laboratory of Neuropharmacology, Department of Physiological Sciences, University of Brasília, Brasília, DF, 70910-900, Brazil
| | - Jacqueline C G Moser
- Laboratory of Neuropharmacology, Department of Physiological Sciences, University of Brasília, Brasília, DF, 70910-900, Brazil
| | - Danubia B Martins
- Department of Physics, IBILCE, São Paulo State University, São José do Rio Preto, SP, 15054-000, Brazil
| | | | - Marisa Rangel
- Immunopathology Laboratory, Butantan Institute, Sao Paulo, SP, 05503-900, Brazil
| | - Luiza C Coelho
- Laboratory of Applied Immunology, Department of Cell Biology, University of Brasilia, Brasilia, DF, 70910-900, Brazil
| | - Karina S Simon
- Laboratory of Applied Immunology, Department of Cell Biology, University of Brasilia, Brasilia, DF, 70910-900, Brazil
| | - Veronica M Amado
- Faculty of Medicine and University Hospital of Brasília, University of Brasilia, Brasilia, DF, 79910-900, Brazil
| | - Jessica de A I Muller
- Laboratory of Pharmacology and Inflammation FACFAN, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, 79070-900, Brazil
| | - Johannes Koehbach
- Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland, Brisbane, QLD, 4072, Australia
| | - Rink-Jan Lohman
- School of Pharmacy, The University of Queensland, Brisbane, QLD, 4072, Australia
| | - Peter J Cabot
- School of Pharmacy, The University of Queensland, Brisbane, QLD, 4072, Australia
| | - Irina Vetter
- Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland, Brisbane, QLD, 4072, Australia
| | - David J Craik
- Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland, Brisbane, QLD, 4072, Australia
| | - Monica C Toffoli-Kadri
- Laboratory of Pharmacology and Inflammation FACFAN, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, 79070-900, Brazil
| | - Victoria Monge-Fuentes
- Laboratory of Neuropharmacology, Department of Physiological Sciences, University of Brasília, Brasília, DF, 70910-900, Brazil
| | - Jair T Goulart
- Laboratory of Neuropharmacology, Department of Physiological Sciences, University of Brasília, Brasília, DF, 70910-900, Brazil
| | - Elisabeth F Schwartz
- Laboratory of Neuropharmacology, Department of Physiological Sciences, University of Brasília, Brasília, DF, 70910-900, Brazil
| | - Luciano P Silva
- Laboratory of Nanobiotechnology, Embrapa Genetic Resources and Biotechnology, Brasília, DF, 70770917, Brazil
| | - Anamelia L Bocca
- Laboratory of Applied Immunology, Department of Cell Biology, University of Brasilia, Brasilia, DF, 70910-900, Brazil
| | - Márcia R Mortari
- Laboratory of Neuropharmacology, Department of Physiological Sciences, University of Brasília, Brasília, DF, 70910-900, Brazil.
| |
Collapse
|
3
|
Lohman RJ, Reddy Tupally K, Kandale A, Cabot PJ, Parekh HS. Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapy. Front Pharmacol 2023; 14:1150313. [PMID: 36937883 PMCID: PMC10020352 DOI: 10.3389/fphar.2023.1150313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Accepted: 02/15/2023] [Indexed: 03/06/2023] Open
Abstract
Kappa opioid receptors have exceptional potential as an analgesic target, seemingly devoid of many problematic Mu receptor side-effects. Kappa-selective, small molecule pharmaceutical agents have been developed, but centrally mediated side-effects limit clinical translation. We modify endogenous dynorphin peptides to improve drug-likeness and develop safer KOP receptor agonists for clinical use. Using rational, iterative design, we developed a series of potent, selective, and metabolically stable peptides from dynorphin 1-7. Peptides were assessed for in vitro cAMP-modulation against three opioid receptors, metabolic stability, KOP receptor selectivity, desensitisation and pERK-signalling capability. Lead peptides were evaluated for in vivo efficacy in a rat model of inflammatory nociception. A library of peptides was synthesised and assessed for pharmacological and metabolic stability. Promising peptide candidates showed low nanomolar KOP receptor selectivity in cAMP assay, and improved plasma and trypsin stability. Selected peptides showed bias towards cAMP signalling over pERK activity, also demonstrating reduced desensitisation. In vivo, two peptides showed significant opioid-like antinociception comparable to morphine and U50844H. These highly potent and metabolically stable peptides are promising opioid analgesic leads for clinical translation. Since they are somewhat biased peptide Kappa agonists they may lack many significant side-effects, such as tolerance, addiction, sedation, and euphoria/dysphoria, common to opioid analgesics.
Collapse
|
4
|
Antiallodynic effects of the selective NaV1.7 inhibitor Pn3a in a mouse model of acute postsurgical pain: evidence for analgesic synergy with opioids and baclofen. Pain 2020; 160:1766-1780. [PMID: 31335646 DOI: 10.1097/j.pain.0000000000001567] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Pain is the leading cause of disability in the developed world but remains a poorly treated condition. Specifically, postsurgical pain continues to be a frequent and undermanaged condition. Here, we investigate the analgesic potential of pharmacological NaV1.7 inhibition in a mouse model of acute postsurgical pain, based on incision of the plantar skin and underlying muscle of the hind paw. We demonstrate that local and systemic treatment with the selective NaV1.7 inhibitor μ-theraphotoxin-Pn3a is effectively antiallodynic in this model and completely reverses mechanical hypersensitivity in the absence of motor adverse effects. In addition, the selective NaV1.7 inhibitors ProTx-II and PF-04856264 as well as the clinical candidate CNV1014802 also reduced mechanical allodynia. Interestingly, co-administration of the opioid receptor antagonist naloxone completely reversed analgesic effects of Pn3a, indicating an involvement of endogenous opioids in the analgesic activity of Pn3a. In addition, we found superadditive antinociceptive effects of subtherapeutic Pn3a doses not only with the opioid oxycodone but also with the GABAB receptor agonist baclofen. Transcriptomic analysis of gene expression changes in dorsal root ganglia of mice after surgery did not reveal any changes in mRNA expression of endogenous opioids or opioid receptors; however, several genes involved in pain, including Runx1 (Runt related transcription factor 1), Cacna1a (CaV2.1), and Cacna1b (CaV2.2), were downregulated. In summary, these findings suggest that pain after surgery can be successfully treated with NaV1.7 inhibitors alone or in combination with baclofen or opioids, which may present a novel and safe treatment strategy for this frequent and poorly managed condition.
Collapse
|
5
|
Abstract
This paper is the fortieth consecutive installment of the annual anthological review of research concerning the endogenous opioid system, summarizing articles published during 2017 that studied the behavioral effects of molecular, pharmacological and genetic manipulation of opioid peptides and receptors as well as effects of opioid/opiate agonists and antagonists. The review is subdivided into the following specific topics: molecular-biochemical effects and neurochemical localization studies of endogenous opioids and their receptors (1), the roles of these opioid peptides and receptors in pain and analgesia in animals (2) and humans (3), opioid-sensitive and opioid-insensitive effects of nonopioid analgesics (4), opioid peptide and receptor involvement in tolerance and dependence (5), stress and social status (6), learning and memory (7), eating and drinking (8), drug abuse and alcohol (9), sexual activity and hormones, pregnancy, development and endocrinology (10), mental illness and mood (11), seizures and neurologic disorders (12), electrical-related activity and neurophysiology (13), general activity and locomotion (14), gastrointestinal, renal and hepatic functions (15), cardiovascular responses (16), respiration and thermoregulation (17), and immunological responses (18).
Collapse
Affiliation(s)
- Richard J Bodnar
- Department of Psychology and Neuropsychology Doctoral Sub-Program, Queens College, City University of New York, CUNY, 65-30 Kissena Blvd., Flushing, NY, 11367, United States.
| |
Collapse
|
6
|
Huang J, Ren Y, Xu Y, Chen T, Xia TC, Li Z, Zhao J, Hua F, Sheng S, Xia Y. The delta-opioid receptor and Parkinson's disease. CNS Neurosci Ther 2018; 24:1089-1099. [PMID: 30076686 PMCID: PMC6489828 DOI: 10.1111/cns.13045] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Revised: 07/10/2018] [Accepted: 07/15/2018] [Indexed: 12/15/2022] Open
Abstract
Parkinson's disease (PD) is a common degenerative neurological disease leading to a series of familial, medical, and social problems. Although it is known that the major characteristics of PD pathophysiology are the dysfunction of basal ganglia due to injury/loss of dopaminergic neurons in the substantia nigra pars compacta dopaminergic and exhaustion of corpus striatum dopamine, therapeutic modalities for PD are limited in clinical settings up to date. It is of utmost importance to better understand PD pathophysiology and explore new solutions for this serious neurodegenerative disorder. Our recent work and those of others suggest that the delta-opioid receptor (DOR) is neuroprotective and serves an antiparkinsonism role in the brain. This review summarizes recent progress in this field and explores potential mechanisms for DOR-mediated antiparkinsonism.
Collapse
Affiliation(s)
- Jin‐Zhong Huang
- The Third Affiliated Hospital of Soochow UniversityChangzhouJiangsuChina
| | - Yi Ren
- The Third Affiliated Hospital of Soochow UniversityChangzhouJiangsuChina
| | - Yuan Xu
- The Third Affiliated Hospital of Soochow UniversityChangzhouJiangsuChina
| | - Tao Chen
- Hainan General HospitalHaikouHainanChina
| | | | - Zhuo‐Ri Li
- Hainan General HospitalHaikouHainanChina
| | | | - Fei Hua
- The Third Affiliated Hospital of Soochow UniversityChangzhouJiangsuChina
| | - Shi‐Ying Sheng
- The Third Affiliated Hospital of Soochow UniversityChangzhouJiangsuChina
| | - Ying Xia
- Shanghai Key Laboratory of Acupuncture Mechanism and Acupoint FunctionFudan UniversityShanghaiChina
- Department of Aeronautics and AstronauticsFudan UniversityShanghaiChina
| |
Collapse
|
7
|
Imam MZ, Kuo A, Ghassabian S, Smith MT. Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression. Neuropharmacology 2017; 131:238-255. [PMID: 29273520 DOI: 10.1016/j.neuropharm.2017.12.032] [Citation(s) in RCA: 84] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2017] [Revised: 12/18/2017] [Accepted: 12/19/2017] [Indexed: 02/06/2023]
Abstract
Opioids evoke analgesia through activation of opioid receptors (predominantly the μ opioid receptor) in the central nervous system. Opioid receptors are abundant in multiple regions of the central nervous system and the peripheral nervous system including enteric neurons. Opioid-related adverse effects such as constipation, nausea, and vomiting pose challenges for compliance and continuation of the therapy for chronic pain management. In the post-operative setting opioid-induced depression of respiration can be fatal. These critical limitations warrant a better understanding of their underpinning cellular and molecular mechanisms to inform the design of novel opioid analgesic molecules that are devoid of these unwanted side-effects. Research efforts on opioid receptor signalling in the past decade suggest that differential signalling pathways and downstream molecules preferentially mediate distinct pharmacological effects. Additionally, interaction among opioid receptors and, between opioid receptor and non-opioid receptors to form signalling complexes shows that opioid-induced receptor signalling is potentially more complicated than previously thought. This complexity provides an opportunity to identify and probe relationships between selective signalling pathway specificity and in vivo production of opioid-related adverse effects. In this review, we focus on current knowledge of the mechanisms thought to transduce opioid-induced gastrointestinal adverse effects (constipation, nausea, vomiting) and respiratory depression.
Collapse
Affiliation(s)
- Mohammad Zafar Imam
- Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia; UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia
| | - Andy Kuo
- UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia
| | - Sussan Ghassabian
- UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia
| | - Maree T Smith
- UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia; School of Pharmacy, Faculty of Health and Behavioural Sciences, The University of Queensland, Brisbane, QLD, Australia.
| |
Collapse
|